Cantargia announces final outcome of the company's significantly oversubscribed rights issue - Seite 2

As a result of the fully subscribed Rights Issue, Cantargia's share capital will increase by SEK 5,343,612.64 to SEK 13,359,031.60 and the number of shares and votes will increase by 66,795,158 to 166,987,895.

Those who have subscribed for shares without the support of subscription rights will be allotted shares in accordance with the principles set out in the prospectus published on 22 July 2022. Notice of allotment to the persons who have subscribed for shares without the support of subscription rights is expected to be distributed today, 12 August 2022. Subscribed and allotted shares must be paid for in cash in accordance with the instructions on the settlement note sent to the subscriber. Investors who have subscribed through a nominee will be notified of the allotment in accordance with their respective nominee's procedures. Only those who have been allotted shares will be notified.

The last day for trading in paid subscribed shares (BTA) was on 11 August 2022. The new shares subscribed for with the support of subscription rights are expected to be registered with the Swedish Companies Registration Office around 16 August 2022 and expected to start trading on Nasdaq Stockholm as of 17 August 2022. The new shares subscribed for without the support of subscription rights are expected to be registered with the Swedish Companies Registration Office around 18 August 2022 and expected to start trading on Nasdaq Stockholm as of 26 August 2022.

Advisers

The Company has engaged Barclays Bank Ireland PLC and Carnegie Investment Bank AB (publ) as Joint Global Coordinators and Bookrunners in conjunction with the Rights Issue. Advokatfirman Vinge acted as legal counsel to the Company and Baker & McKenzie Advokatbyrå KB acted as legal counsel to the Joint Global Coordinators.

For further information, please contact:

Göran Forsberg, CEO
Mobile: [phone]
E-mail: [e-mail]

The information was submitted for publication, through the agency of the contact person set out above, at 08:00 CEST on 12 August 2022.

About Cantargia

Cantargia AB (publ), reg. no. 556791-6019, is a biotechnology company that develops antibody-based treatments for life-threatening diseases and has established a platform based on the protein IL1RAP, involved in a number of cancer forms and inflammatory diseases. The main project, the antibody nadunolimab, is being studied clinically in combination with chemotherapy or immune therapy with a primary focus on non-small cell lung cancer and pancreatic cancer. Positive interim data from the combination with chemotherapy indicate stronger efficacy than would be expected from chemotherapy alone. Cantargia's second project, the antibody CAN10, addresses treatment of serious autoimmune/inflammatory diseases, with initial focus on systemic sclerosis and myocarditis.